层层的皮肤状水凝用于长效药物释放,以实现分阶段的慢性伤口愈合
1Department of Nursing, Zhejiang Provincial People's Hospital, Hangzhou, 310014, China; Nursing College, Hangzhou Normal University, Hangzhou, China.
International journal of biological macromolecules
|February 9, 2026
概括
这项研究引入了一种用于慢性伤口的新型生物仿真水凝包裹. 先进的材料提供持续的药物释放,并通过抗炎和血管重建效应促进愈合.
科学领域:
- 生物材料科学 生物材料科学
- 再生医学是一种再生医学.
- 伤口愈合 伤口愈合
背景情况:
- 慢性伤口对健康构成重大挑战,需要先进的治疗方法.
- 现有的伤口带努力维持治疗药物度,阻碍有效的愈合.
- 迫切需要长效的治疗策略来管理复杂的伤口愈合过程.
研究的目的:
- 开发一种创新的仿生皮肤双层水凝,用于慢性伤口管理.
- 创建一种能够持续释放药物并促进组织再生的包裹.
- 为了研究水凝成分对伤口修复的协同作用.
主要方法:
- 使用GelMA,碳氧化纤维素纳米晶体 (CNC) 和荷载在多孔多胺纳米粒子 (PDA@NPs) 中的肝素硫酸盐 (HS) 制造双层水凝.
- 对上皮表皮仿真层进行光交叉连接,对下皮仿真层进行自发扩散.
- 描述水凝的结构,药物负载能力和释放动力学.
主要成果:
- 上层有效地模仿表皮屏障,防止二次损伤.
- 下层利用多孔的PDA@NPs,通过度梯度实现高HS负载和持续的药物释放.
- 开发的水凝显示出协同作用,通过抗炎和血管重建机制加速伤口修复.
结论:
- 仿生皮肤双层水凝为慢性伤口管理提供了安全有效的策略.
- 该系统提供持续释放和促进愈合机制的能力解决了当前治疗方法的局限性.
- 这种创新的水凝有望改善慢性伤口护理患者的治疗结果.
相关概念视频
Drugs Acting on Autonomic Ganglia: Stimulants
2.1K
Ganglionic stimulants activate NM nicotinic receptors in autonomic ganglia, falling into two categories: nicotine mimetics [e.g., lobeline, dimethylpiperazine, tetramethylammonium] and muscarinic receptor agonists [e.g., muscarine, methacholine]. The first category's action is rapid and blocked by nicotinic receptor antagonists, while the second category's action is delayed and blocked by atropine-like agents. Nicotine, an alkaloid, affects the heart rate by stimulating...
2.1K
Drugs Acting on Autonomic Ganglia: Blockers
1.7K
Ganglionic blockers inhibit autonomic activity by blocking nicotinic receptors in the autonomic ganglia, suppressing impulse transmission. These blockers lack selectivity between sympathetic and parasympathetic ganglia and are ineffective as neuromuscular junction antagonists. They can be categorized into two groups:
1.7K
Drugs Affecting Neurotransmitter Release or Uptake
1.6K
Certain drugs can affect how neurotransmitters called catecholamines, are released or taken back up in the adrenergic neuron. They can have different effects on the body's sympathetic transmission. Reserpine, a natural compound found in the Rauwolfia shrub, blocks a transporter called vesicular monoamine transporter (VMAT), which leads to a buildup of catecholamines in the cell and reduces sympathetic transmission. Another drug called guanethidine works in multiple ways, including blocking...
1.6K
Forces Acting on Chromosomes
4.0K
During mitosis, chromosome movements occur through the interplay of multiple piconewton level forces. In prometaphase, these forces help in chromosome assembly or congression at the equatorial plane, eventually leading to their alignment at the metaphase plate. The forces acting on the chromosomes are space and time-dependent; therefore, they vary with the position of the chromosomes as the cell progresses through mitosis.
Microtubules and motor proteins exert two types of forces on...
Microtubules and motor proteins exert two types of forces on...
4.0K
In Vitro Drug Release Testing: Overview, Development and Validation
363
In vitro dissolution and drug release tests assess how quickly and how much of a drug is released from its dosage form into an aqueous medium under standardized laboratory conditions. These tests are essential tools in pharmaceutical development and quality assurance, offering insight into the drug's performance before clinical use.During formulation development, dissolution testing identifies incomplete or inconsistent drug release issues. It also supports decisions on selecting the optimal...
363
Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein
926
Antiepileptic drugs, such as levetiracetam (Keppra) and brivaracetam (Briviact), have emerged as crucial tools in managing epilepsy. These medications exert their therapeutic effects by targeting the synaptic vesicle protein SV2A, a transmembrane glycoprotein primarily found in the brain.
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
926


